Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT-902
- Development stage
- Preclinical
- Lead developer
- Alpha Cancer Technologies
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
ACT-902 is an alpha-fetoprotein (AFP)-drug conjugate developed by Alpha Cancer Technologies for the treatment of solid and liquid tumors. It consists of a recombinant human AFP protein linked to a thapsigargin payload. ACT-902 targets the AFP receptor (AFPR), which is highly expressed on the surface of many types of cancer cells (including over 80% of solid and liquid tumors) but is absent on healthy adult cells. Upon binding to the AFPR, the conjugate is internalized, releasing thapsigargin, a potent inhibitor of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump, leading to cell death. Preclinical studies indicate that ACT-902 also reduces Myeloid-Derived Suppressor Cells (MDSCs) in the tumor microenvironment, potentially overcoming immune suppression and enhancing the host's immune response against the tumor.
- Other names
- AFP-thapsigargin conjugate
02
Targets
ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)RPSA (37/67 kDa laminin receptor)
Beyond the preview
Go deeper on ACT-902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT-902.